|
1
|
Tritschler T, Kraaijpoel N, Le Gal G and
Wells PS: Venous thromboembolism: Advances in diagnosis and
treatment. JAMA. 320:1583–1594. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Heit JA: Epidemiology of venous
thromboembolism. Nat Rev Cardiol. 12:464–474. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bartholomew JR: Update on the management
of venous thromboembolism. Cleve Clin J Med. 84:39–46.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kniffin WD Jr, Baron JA, Barrett J,
Birkmeyer JD and Anderson FA Jr: The epidemiology of diagnosed
pulmonary embolism and deep venous thrombosis in the elderly. Arch
Intern Med. 154:861–866. 1994.PubMed/NCBI
|
|
5
|
Silverstein MD, Heit JA, Mohr DN,
Petterson TM, O'Fallon WM and Melton LJ III: Trends in the
incidence of deep vein thrombosis and pulmonary embolism: A 25 year
population-based study. Arch Intern Med. 158:585–593.
1998.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kumasaka N, Sakuma M and Shirato K:
Clinical features and predictors of in-hospital mortality in
patients with acute and chronic pulmonary thromboembolism. Intern
Med. 39:1038–1043. 2000.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kiluk IE, Krajewska A, Kosacka U, Tycińska
A, Milewski R, Musiał W and Sobkowicz B: Different manifestations
of pulmonary embolism in younger compared to older patients:
Clinical presentation, prediction rules and long-term outcomes. Adv
Med Sci. 62:254–258. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jaquet E, Tritschler T, Stalder O,
Limacher A, Méan M, Rodondi N and Aujesky D: Prediction of
short-term prognosis in elderly patients with acute pulmonary
embolism: Validation of the RIETE score. J Thromb Haemost.
16:1313–1320. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Engbers MJ, van Hylckama Vlieg A and
Rosendaal FR: Venous thrombosis in the elderly: Incidence, risk
factors and risk groups. J Thromb Haemost. 8:2105–2112.
2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gallus A, Jackaman J, Tillett J, Mills W
and Wycherley A: Safety and efficacy of warfarin started early
after submassive venous thrombosis or pulmonary embolism. Lancet.
2:1293–1296. 1986.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lotke PA and Ecker ML:
Low-Molecular-weight heparin vs. Warfarin for prophylaxis against
deep-vein thrombosis. N Engl J Med. 330(863)1994.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Buller HR, Lensing AW, Prins MH, Agnelli
G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S and
Segers A: Einstein-DVT Dose-Ranging Study investigators. A
dose-ranging study evaluating once-daily oral administration of the
factor xa inhibitor rivaroxaban in the treatment of patients with
acute symptomatic deep vein thrombosis: The Einstein-DVT
dose-ranging study. Blood. 112:2242–2247. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Scaglione F: New oral anticoagulants:
Comparative pharmacology with vitamin K antagonists. Clin
Pharmacokinet. 52:69–82. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
EINSTEIN Investigators. Bauersachs R,
Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing
AW, Misselwitz F, Prins MH, et al: Oral rivaroxaban for symptomatic
venous thromboembolism. N Engl J Med. 363:2499–2510.
2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
EINSTEIN–PE Investigators. Buller HR,
Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J,
Verhamme P, Wells P, et al: Oral rivaroxaban for the treatment of
symptomatic pulmonary embolism. N Engl J Med. 366:1287–1297.
2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kearon C, Akl EA, Ornelas J, Blaivas A,
Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, et
al: Antithrombotic therapy for VTE disease: CHEST guideline and
expert panel report. Chest. 149:315–352. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Konstantinides SV, Torbicki A, Agnelli G,
Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M,
Kucher N, et al: 2014 ESC guidelines on the diagnosis and
management of acute pulmonary embolism. Eur Heart J. 35:3033–3069.
2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Mazzolai L, Aboyans V, Ageno W, Agnelli G,
Alatri A, Bauersachs R, Brekelmans MPA, Büller HR, Elias A, Farge
D, et al: Diagnosis and management of acute deep vein thrombosis: A
joint consensus document from the European society of cardiology
working groups of aorta and peripheral vascular diseases and
pulmonary circulation and right ventricular function. Eur Heart J.
39:4208–4218. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wang Y, Wang C, Chen Z, Zhang J, Liu Z,
Jin B, Ying K, Liu C, Shao Y, Jing Z, et al: Rivaroxaban for the
treatment of symptomatic deep-vein thrombosis and pulmonary
embolism in Chinese patients: A subgroup analysis of the EINSTEIN
DVT and PE studies. Thromb J. 11(25)2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhou Q, Wu Y, Jiang X, Liu X, Lei H, Jing
Z and Huang W: [Efficacy comparison of 3 rivaroxaban regimen in
patients with venous thromboembolism]. Zhonghua Xin Xue Guan Bing
Za Zhi. 43:782–784. 2015.PubMed/NCBI
|
|
21
|
Song Z, Wu H, Cao H, Tang M, Yang S and
Qin L: Nephrotic syndrome with acute pulmonary embolism in young
adults: Two case reports. Medicine (Baltimore).
97(e11495)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Jara-Palomares L, Sanchez-Oro-Gomez R,
Elias-Hernandez T, Morillo-Guerrero R, Ferrer-Galvan M,
Asensio-Cruz MI, Barrot-Cortes E and Otero-Candelera R: Rivaroxaban
for the treatment of venous thromboembolism. A ‘real-life’
perspective in 103 patients. Thromb Res. 134:617–621.
2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pesavento R and Iori I: Gruppo Italiano
Survey TEV. [Use of rivaroxaban in real-life treatment of venous
thromboembolism: Results of the TEV Survey, an Italian
epidemiological study]. G Ital Cardiol (Rome). 18:239–246.
2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Naess IA, Christiansen SC, Romundstad P,
Cannegieter SC, Rosendaal FR and Hammerstrom J: Incidence and
mortality of venous thrombosis: A population-based study. J Thromb
Haemost. 5:692–699. 2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Anderson FA Jr, Wheeler HB, Goldberg RJ,
Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A and Dalen JE: A
population-based perspective of the hospital incidence and
case-fatality rates of deep vein thrombosis and pulmonary embolism.
The worcester DVT study. Arch Intern Med. 151:933–938.
1991.PubMed/NCBI
|
|
26
|
Lucena J, Rico A, Vazquez R, Marín R,
Martínez C, Salguero M and Miguel L: Pulmonary embolism and
sudden-unexpected death: Prospective study on 2477 forensic
autopsies performed at the institute of legal medicine in seville.
J Forensic Leg Med. 16:196–201. 2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Heredia V, Ramalho M, Zapparoli M and
Semelka RC: Incidence of pulmonary embolism and other chest
findings in younger patients using multidetector computed
tomography. Acta Radiol. 51:402–406. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kuroki M, Nishino M, Takahashi M, Mori Y,
Raptopoulos VD, Boiselle PM, Tamura S and Hatabu H: Incidence of
pulmonary embolism in younger versus older patients using CT. J
Thorac Imaging. 21:167–171. 2006.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Castelli R, Bergamaschini L, Sailis P,
Pantaleo G and Porro F: The impact of an aging population on the
diagnosis of pulmonary embolism: Comparison of young and elderly
patients. Clin Appl Thromb Hemost. 15:65–72. 2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Roupie AL, Dossier A, Goulenok T,
Perozziello A, Papo T and Sacre K: First venous thromboembolism in
admitted patients younger than 50 years old. Eur J Intern Med.
34:e18–e20. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Cefalo P, Weinberg I, Hawkins BM,
Hariharan P, Okechukwu I, Parry BA, Chang Y, Rosovsky R, Liu SW,
Jaff MR and Kabrhel C: A comparison of patients diagnosed with
pulmonary embolism who are ≥65 years with patients ≥65 years. Am J
Cardiol. 115:681–686. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kreidy R, Salameh P and Waked M: Lower
extremity venous thrombosis in patients younger than 50 years of
age. Vasc Health Risk Manag. 8:161–167. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tsai AW, Cushman M, Rosamond WD, Heckbert
SR, Polak JF and Folsom AR: Cardiovascular risk factors and venous
thromboembolism incidence: The longitudinal investigation of
thromboembolism etiology. Arch Intern Med. 162:1182–1189.
2002.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Theilade J, Winkel BG, Holst AG,
Tfelt-Hansen J, Svendsen JH and Haunso S: A nationwide,
retrospective analysis of symptoms, comorbidities, medical care and
autopsy findings in cases of fatal pulmonary embolism in younger
patients. J Thromb Haemost. 8:1723–1729. 2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
White RH, Zhou H and Murin S: Death due to
recurrent thromboembolism among younger healthier individuals
hospitalized for idiopathic pulmonary embolism. Thromb Haemost.
99:683–690. 2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Stoeva N, Kirova G, Staneva M, Lekova D,
Penev A and Bakalova R: Recognition of unprovoked (idiopathic)
pulmonary embolism-Prospective observational study. Respir Med.
135:57–61. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bruwer G, Limperger V, Kenet G,
Klostermeier UC, Shneyder M, Degenhardt F, Finckh U, Heller C,
Holzhauer S, Trappe R, et al: Impact of high risk thrombophilia
status on recurrence among children and adults with VTE: An
observational multicenter cohort study. Blood Cells Mol Dis.
62:24–31. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Alhassan S, Pelinescu A, Gandhi V, Naddour
M, Singh AC and Bihler E: Clinical presentation and risk factors of
venous thromboembolic disease. Crit Care Nurs Q. 40:201–209.
2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
De Stefano V, Simioni P, Rossi E, Tormene
D, Za T, Pagnan A and Leone G: The risk of recurrent venous
thromboembolism in patients with inherited deficiency of natural
anticoagulants antithrombin, protein C and protein S.
Haematologica. 91:695–698. 2006.PubMed/NCBI
|
|
40
|
Segal JB, Brotman DJ, Necochea AJ, Emadi
A, Samal L, Wilson LM, Crim MT and Bass EB: Predictive value of
factor V Leiden and prothrombin G20210A in adults with venous
thromboembolism and in family members of those with a mutation: A
systematic review. JAMA. 301:2472–2485. 2009.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lijfering WM, Middeldorp S, Veeger NJ,
Hamulyák K, Prins MH, Büller HR and van der Meer J: Risk of
recurrent venous thrombosis in homozygous carriers and double
heterozygous carriers of factor V leiden and prothrombin G20210A.
Circulation. 121:1706–1712. 2010.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kyrle PA, Minar E, Hirschl M, Bialonczyk
C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K and
Eichinger S: High plasma levels of factor VIII and the risk of
recurrent venous thromboembolism. N Engl J Med. 343:457–462.
2000.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Eischer L, Gartner V, Schulman S, Kyrle PA
and Eichinger S: AUREC-FVIII Investigators. 6 versus 30 months
anticoagulation for recurrent venous thrombosis in patients with
high factor VIII. Ann Hematol. 88:485–490. 2009.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Weltermann A, Eichinger S, Bialonczyk C,
Minar E, Hirschl M, Quehenberger P, Schönauer V and Kyrle PA: The
risk of recurrent venous thromboembolism among patients with high
factor IX levels. J Thromb Haemost. 1:28–32. 2003.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Gjonbrataj E, Kim JN, Gjonbrataj J, Jung
HI, Kim HJ and Choi WI: Risk factors associated with provoked
pulmonary embolism. Korean J Intern Med. 32:95–101. 2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Baglin T, Luddington R, Brown K and Baglin
C: Incidence of recurrent venous thromboembolism in relation to
clinical and thrombophilic risk factors: Prospective cohort study.
Lancet. 362:523–526. 2003.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Palareti G, Legnani C, Cosmi B, Valdré L,
Lunghi B, Bernardi F and Coccheri S: Predictive value of D-dimer
test for recurrent venous thromboembolism after anticoagulation
withdrawal in subjects with a previous idiopathic event and in
carriers of congenital thrombophilia. Circulation. 108:313–318.
2003.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Christiansen SC, Cannegieter SC, Koster T,
Vandenbroucke JP and Rosendaal FR: Thrombophilia, clinical factors,
and recurrent venous thrombotic events. JAMA. 293:2352–2361.
2005.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Kyrle PA, Rosendaal FR and Eichinger S:
Risk assessment for recurrent venous thrombosis. Lancet.
376:2032–2039. 2010.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Cannegieter SC and van Hylckama Vlieg A:
Venous thrombosis: Understanding the paradoxes of recurrence. J
Thromb Haemost. 11:161–169. 2013.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Kearon C, Ageno W, Cannegieter SC, Cosmi
B, Geersing GJ and Kyrle PA: Subcommittees on Control of
Anticoagulation and Predictive and Diagnostic Variables in
Thrombotic Disease. Categorization of patients as having provoked
or unprovoked venous thromboembolism: Guidance from the SSC of
ISTH. J Thromb Haemost. 14:1480–1483. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Iorio A, Kearon C, Filippucci E, Marcucci
M, Macura A, Pengo V, Siragusa S and Palareti G: Risk of recurrence
after a first episode of symptomatic venous thromboembolism
provoked by a transient risk factor: A systematic review. Arch
Intern Med. 170:1710–1716. 2010.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Prandoni P, Lensing AW, Piccioli A,
Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins
MH, Noventa F and Girolami A: Recurrent venous thromboembolism and
bleeding complications during anticoagulant treatment in patients
with cancer and venous thrombosis. Blood. 100:3484–3488.
2002.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Heit JA, Mohr DN, Silverstein MD,
Petterson TM, O'Fallon WM and Melton LJ III: Predictors of
recurrence after deep vein thrombosis and pulmonary embolism: A
population-based cohort study. Arch Intern Med. 160:761–768.
2000.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Pomp ER, Rosendaal FR and Doggen CJ:
Smoking increases the risk of venous thrombosis and acts
synergistically with oral contraceptive use. Am J Hematol.
83:97–102. 2008.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Blondon M, Wiggins KL, McKnight B, Psaty
BM, Rice KM, Heckbert SR and Smith NL: The association of smoking
with venous thrombosis in women. A population-based, case-control
study. Thromb Haemost. 109:891–896. 2013.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Blix K, Brækkan SK, le Cessie S,
Skjeldestad FE, Cannegieter SC and Hansen JB: The increased risk of
venous thromboembolism by advancing age cannot be attributed to the
higher incidence of cancer in the elderly: The tromso study. Eur J
Epidemiol. 29:277–284. 2014.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Kröger K, Moerchel C, Moysidis T and
Santosa F: Incidence rate of pulmonary embolism in Germany: Data
from the federal statistical office. J Thromb Thrombolysis.
29:349–353. 2010.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Green RM, Meyer TJ, Dunn M and Glassroth
J: Pulmonary embolism in younger adults. Chest. 101:1507–1511.
1992.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Arima M, Kanoh T, Takagi A, Tanimoto K,
Oigawa T and Matsuda S: Clinical features of acute pulmonary
thromboembolism in younger patients. Circ J. 67:330–333.
2003.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Kappelman MD, Horvath-Puho E, Sandler RS,
Rubin DT, Ullman TA, Pedersen L, Baron JA and Sørensen HT:
Thromboembolic risk among danish children and adults with
inflammatory bowel diseases: A population-based nationwide study.
Gut. 60:937–943. 2011.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Lim W: Antiphospholipid syndrome.
Hematology. Hematology Am Soc Hematol Educ Program. 2013:675–680.
2013.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Spencer FA, Gore JM, Lessard D, Emery C,
Pacifico L, Reed G, Gurwitz JH and Goldberg RJ: Venous
thromboembolism in the elderly. A community-based perspective.
Thromb Haemost. 100:780–788. 2008.PubMed/NCBI
|
|
64
|
Ageno W, Agnelli G, Imberti D, Moia M,
Palareti G, Pistelli R, Rossi R and Verso M: MASTER Investigators.
Risk factors for venous thromboembolism in the elderly: Results of
the master registry. Blood Coagul Fibrinolysis. 19:663–667.
2008.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Wood KE: Major pulmonary embolism: Review
of a pathophysiologic approach to the golden hour of
hemodynamically significant pulmonary embolism. Chest. 121:877–905.
2002.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Mauritz GJ, Marcus JT, Westerhof N,
Postmus PE and Vonk-Noordegraaf A: Prolonged right ventricular
post-systolic isovolumic period in pulmonary arterial hypertension
is not a reflection of diastolic dysfunction. Heart. 97:473–478.
2011.PubMed/NCBI View Article : Google Scholar
|
|
67
|
McIntyre KM and Sasahara AA: The
hemodynamic response to pulmonary embolism in patients without
prior cardiopulmonary disease. Am J Cardiol. 28:288–294.
1971.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Lankhaar JW, Westerhof N, Faes TJ, Marques
KM, Marcus JT, Postmus PE and Vonk-Noordegraaf A: Quantification of
right ventricular afterload in patients with and without pulmonary
hypertension. Am J Physiol Heart Circ Physiol. 291:H1731–H1737.
2006.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Lankeit M, Jimenez D, Kostrubiec M, Dellas
C, Hasenfuss G, Pruszczyk P and Konstantinides S: Predictive value
of the high-sensitivity troponin T assay and the simplified
pulmonary embolism severity index in hemodynamically stable
patients with acute pulmonary embolism: A prospective validation
study. Circulation. 124:2716–2724. 2011.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Mehta NJ, Jani K and Khan IA: Clinical
usefulness and prognostic value of elevated cardiac troponin I
levels in acute pulmonary embolism. Am Heart J. 145:821–825.
2003.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Burrowes KS, Clark AR and Tawhai MH: Blood
flow redistribution and ventilation-perfusion mismatch during
embolic pulmonary arterial occlusion. Pulm Circ. 1:365–376.
2011.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Gisselbrecht M, Diehl JL, Meyer G,
Collignon MA and Sors H: Clinical presentation and results of
thrombolytic therapy in older patients with massive pulmonary
embolism: A comparison with non-elderly patients. J Am Geriatr Soc.
44:189–193. 1996.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Timmons S, Kingston M, Hussain M, Kelly H
and Liston R: Pulmonary embolism: Differences in presentation
between older and younger patients. Age Ageing. 32:601–605.
2003.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Parenti NBA, Bonarelli S and Fanciulli A:
Pulmonary embolism in younger adults: Clinical presentation and
comparison of two scoring systems used to estimate pretest
probability of disease in the emergency department. Ann Emerg Med.
44(36)2004.
|
|
75
|
Witt DM, Clark NP, Kaatz S, Schnurr T and
Ansell JE: Guidance for the practical management of warfarin
therapy in the treatment of venous thromboembolism. J Thromb
Thrombolysis. 41:187–205. 2016.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Prandoni P, Lensing AW, Büller HR, Carta
M, Cogo A, Vigo M, Casara D, Ruol A and ten Cate JW: Comparison of
subcutaneous low-molecular-weight heparin with intravenous standard
heparin in proximal deep-vein thrombosis. Lancet. 339:441–445.
1992.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Columbus Investigtors. Büller HR, Gent M,
Gallus AS, Ginsberg J, Prins MH and Baildon R: Low-molecular-weight
heparin in the treatment of patients with venous thromboembolism. N
Engl J Med. 337:657–662. 1997.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Prins MH, Lensing AW, Bauersachs R, van
Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL,
Decousus H, Raskob GE, et al: Oral rivaroxaban versus standard
therapy for the treatment of symptomatic venous thromboembolism: A
pooled analysis of the EINSTEIN-DVT and PE randomized studies.
Thromb J. 11(21)2013.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Lopez-Jimenez L, Montero M,
Gonzalez-Fajardo JA, Arcelus JI, Suárez C, Lobo JL, Monreal M and
RIETE Investigators: Venous thromboembolism in very elderly
patients: Findings from a prospective registry (RIETE).
Haematologica. 91:1046–1051. 2006.PubMed/NCBI
|
|
80
|
Lim W, Dentali F, Eikelboom JW and
Crowther MA: Meta-Analysis: Low-molecular-weight heparin and
bleeding in patients with severe renal insufficiency. Ann Intern
Med. 144:673–684. 2006.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Silverstein RL, Bauer KA, Cushman M, Esmon
CT, Ershler WB and Tracy RP: Venous thrombosis in the elderly: More
questions than answers. Blood. 110:3097–3101. 2007.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Agnelli G, Buller HR, Cohen A, Curto M,
Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE,
et al: Oral apixaban for the treatment of acute venous
thromboembolism. N Engl J Med. 369:799–808. 2013.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Hokusai-VTE Investigators. Büller HR,
Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob
GE, Schellong SM, Schwocho L, et al: Edoxaban versus warfarin for
the treatment of symptomatic venous thromboembolism. N Engl J Med.
369:1406–1415. 2013.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Liu X, Johnson M, Mardekian J, Phatak H,
Thompson J and Cohen AT: Apixaban reduces hospitalizations in
patients with venous thromboembolism: An analysis of the apixaban
for the initial management of pulmonary embolism and deep-vein
thrombosis as first-line therapy (AMPLIFY) trial. J Am Heart Assoc.
4(12)2015.PubMed/NCBI View Article : Google Scholar
|
|
85
|
van der Hulle T, Kooiman J, den Exter PL,
Dekkers OM, Klok FA and Huisman MV: Effectiveness and safety of
novel oral anticoagulants as compared with vitamin K antagonists in
the treatment of acute symptomatic venous thromboembolism: A
systematic review and meta-analysis. J Thromb Haemost. 12:320–328.
2014.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Kvasnicka T, Malikova I, Zenahlikova Z,
Kettnerova K, Brzezkova R, Zima T, Ulrych J, Briza J, Netuka I and
Kvasnicka J: Rivaroxaban-metabolism, pharmacologic properties and
drug interactions. Curr Drug Metab. 18:636–642. 2017.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Limdi NA, Beasley TM, Baird MF, Goldstein
JA, McGwin G, Arnett DK, Acton RT and Allon M: Kidney function
influences warfarin responsiveness and hemorrhagic complications. J
Am Soc Nephrol. 20:912–921. 2009.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Steffel J, Verhamme P, Potpara TS,
Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke
H, Roldan-Schilling V, et al: The 2018 European heart rhythm
association practical guide on the use of non-vitamin K antagonist
oral anticoagulants in patients with atrial fibrillation. Eur Heart
J. 39:1330–1393. 2018.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Eriksson BI, Borris LC, Friedman RJ, Haas
S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E,
Misselwitz F, et al: Rivaroxaban versus enoxaparin for
thromboprophylaxis after hip arthroplasty. N Engl J Med.
358:2765–2775. 2008.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Eikelboom JW, Connolly SJ, Bosch J,
Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM,
Anand SS, et al: Rivaroxaban with or without aspirin in stable
cardiovascular disease. N Engl J Med. 377:1319–1330.
2017.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Khorana AA, Berger JS, Wells PS, Seheult
R, Ashton V, Laliberté F, Crivera C, Lejeune D, Schein J, Wildgoose
P, et al: Risk for venous thromboembolism recurrence among
rivaroxaban-treated patients who continued versus discontinued
therapy: Analyses among patients with VTE. Clin Ther. 39:1396–1408.
2017.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Coleman CI, Bunz TJ and Turpie AGG:
Effectiveness and safety of rivaroxaban versus warfarin for
treatment and prevention of recurrence of venous thromboembolism.
Thromb Haemost. 117:1841–1847. 2017.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Larsen TB, Skjøth F, Kjaeldgaard JN, Lip
GYH, Nielsen PB and Sogaard M: Effectiveness and safety of
rivaroxaban and warfarin in patients with unprovoked venous
thromboembolism: A propensity-matched nationwide cohort study.
Lancet Haematol. 4:e237–e244. 2017.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Ageno W, Mantovani LG, Haas S, Kreutz R,
Monje D, Schneider J, van Eickels M, Gebel M, Zell E and Turpie AG:
Safety and effectiveness of oral rivaroxaban versus standard
anticoagulation for the treatment of symptomatic deep-vein
thrombosis (XALIA): An international, prospective,
non-interventional study. Lancet Haematol. 3:e12–e21.
2016.PubMed/NCBI View Article : Google Scholar
|
|
95
|
van Bellen B, Bamber L, Correa de Carvalho
F, Prins M, Wang M and Lensing AW: Reduction in the length of stay
with rivaroxaban as a single-drug regimen for the treatment of deep
vein thrombosis and pulmonary embolism. Curr Med Res Opin.
30:829–837. 2014.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Lefebvre P, Coleman CI, Bookhart BK, Wang
ST, Mody SH, Tran KN, Zhuo DY, Huynh L and Nutescu EA:
Cost-Effectiveness of rivaroxaban compared with enoxaparin plus a
vitamin K antagonist for the treatment of venous thromboembolism. J
Med Econ. 17:52–64. 2014.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Merli GJ, Hollander JE, Lefebvre P,
Laliberté F, Raut MK, Germain G, Bookhart B and Pollack CV: Costs
of hospital visits among patients with deep vein thrombosis treated
with rivaroxaban and LMWH/warfarin. J Med Econ. 19:84–90.
2016.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Kline JA, Nordenholz KE, Courtney DM,
Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR and
Hernandez J: Treatment of submassive pulmonary embolism with
tenecteplase or placebo: Cardiopulmonary outcomes at 3 months:
Multicenter double-blind, placebo-controlled randomized trial. J
Thromb Haemost. 12:459–468. 2014.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Meyer G, Vicaut E, Danays T, Agnelli G,
Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B,
Couturaud F, et al: Fibrinolysis for patients with
intermediate-risk pulmonary embolism. N Engl J Med. 370:1402–1411.
2014.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Bajaj NS, Kalra R, Arora P, Ather S,
Guichard JL, Lancaster WJ, Patel N, Raman F, Arora G, Al Solaiman
F, et al: Catheter-directed treatment for acute pulmonary embolism:
Systematic review and single-arm meta-analyses. Int J Cardiol.
225:128–139. 2016.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Mismetti P, Laporte S, Pellerin O, Ennezat
PV, Couturaud F, Elias A, Falvo N, Meneveau N, Quere I, Roy PM, et
al: Effect of a retrievable inferior vena cava filter plus
anticoagulation vs. anticoagulation alone on risk of recurrent
pulmonary embolism: A randomized clinical trial. JAMA.
313:1627–1635. 2015.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Gnoth MJ, Buetehorn U, Muenster U, Schwarz
T and Sandmann S: In vitro and in vivo P-glycoprotein transport
characteristics of rivaroxaban. J Pharmacol Exp Ther. 338:372–380.
2011.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Song ZK, Cao H, Wei H, Wei Q, Tang M, Yang
S, Liu Y and Qin L: Current status of rivaroxaban in elderly
patients with pulmonary embolism (Review). Exp Ther Med.
19:2817–2825. 2020.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Li SJ, Tu YM, Zhou CS, Zhang LH and Liu
ZH: Risk factors of venous thromboembolism in focal segmental
glomerulosclerosis with nephrotic syndrome. Clin Exp Nephrol.
20:212–217. 2016.PubMed/NCBI View Article : Google Scholar
|
